Sesen Bio Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $127.96 million
- Book Value:
- Revenue TTM:
- $40 million
- Operating Margin TTM:
- Gross Profit TTM:
- $38.02 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Sesen Bio Inc had its IPO on 2014-02-06 under the ticker symbol SESN.
The company operates in the Healthcare sector and Biotechnology industry. Sesen Bio Inc has a staff strength of 17 employees.
Shares of Sesen Bio Inc opened at $0.57 at the start of the last trading session i.e. 2023-03-23.
The stocks traded within a range of $0.57 - $0.63, and closed at $0.63.
This is a +2548.22% increase from the previous day's closing price.
A total volume of 0 shares were traded at the close of the day’s session.
In the last one week, shares of Sesen Bio Inc have increased by +43.55%.
Sesen Bio Inc's Key Ratios
Sesen Bio Inc has a market cap of $127.96 million, indicating a price to book ratio of 0.6445 and a price to sales ratio of 1.7184.
In the last 12-months Sesen Bio Inc’s revenue was $40 million with a gross profit of $38.02 million and an EBITDA of $-38368000. The EBITDA ratio measures Sesen Bio Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Sesen Bio Inc’s operating margin was -95.95% while its return on assets stood at -11.16% with a return of equity of -12.06%.
In Q4, Sesen Bio Inc’s quarterly earnings growth was a negative -71.4% while revenue growth was a negative 100%.
Sesen Bio Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.1 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sesen Bio Inc’s profitability.
Sesen Bio Inc stock is trading at a EV to sales ratio of 0.0786 and a EV to EBITDA ratio of 2.7001. Its price to sales ratio in the trailing 12-months stood at 1.7184.
Sesen Bio Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $189.17 million
- Total Liabilities
- $30.98 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Sesen Bio Inc ended 2023 with $189.17 million in total assets and $0 in total liabilities. Its intangible assets were valued at $189.17 million while shareholder equity stood at $158.19 million.
Sesen Bio Inc ended 2023 with $0 in deferred long-term liabilities, $30.98 million in other current liabilities, 202000.00 in common stock, $-336141000.00 in retained earnings and $0.00 in goodwill. Its cash balance stood at $112.55 million and cash and short-term investments were $166.92 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Sesen Bio Inc’s total current assets stands at $189.14 million while long-term investments were $0 and short-term investments were $54.37 million. Its net receivables were $825000.00 compared to accounts payable of $1.23 million and inventory worth $0.
In 2023, Sesen Bio Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Sesen Bio Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Sesen Bio Inc stock is currently trading at $0.63 per share. It touched a 52-week high of $19.3 and a 52-week low of $19.3. Analysts tracking the stock have a 12-month average target price of $0.6.
Its 50-day moving average was $10.57 and 200-day moving average was $11.93 The short ratio stood at 2.34 indicating a short percent outstanding of 0%.
Around 898.2% of the company’s stock are held by insiders while 1601% are held by institutions.
Frequently Asked Questions About Sesen Bio Inc
Similar Industry Stocks (Biotechnology)
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.